NCT00617799 2023-10-10
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
University of Nebraska
Completed
Clinical Trials
9 trialsNCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00658892 2017-05-25
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT01388569 2017-05-17
Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim
Eastern Cooperative Oncology Group
Completed
NCT01489423 2017-05-17
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim
Eastern Cooperative Oncology Group
Completed
NCT00553306 2017-02-15
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00453050 2015-05-06
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
Phase 1 Completed
NCT01082198 2013-08-26
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00492440 2012-10-18
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
Cytheris SA
Phase 1 Terminated